Do you want to read an article? Please log in or register.
TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer
Breast Cancer
ASCO 2024
Related content
Breast Cancer
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry
Int J Cancer
Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T
doi: 10.1002/ijc.35296
COMMENTED
Breast Cancer
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B, TROPION-Breast01 Investigators
doi: 10.1200/JCO.24.00920
ASCO 2024
Breast Cancer
SACI-IO HR+: Adding pembrolizumab to sacituzumab govitecan shows numerical PFS improvement in HR-positive, HER2-negative breast cancer
ASCO 2024
Breast Cancer
NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer
Breast Cancer
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Clin Cancer Res
Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L
doi: 10.1158/1078-0432.CCR-24-1553
ESMO 2024
Breast Cancer
DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases
ASCO 2024
Breast Cancer
DESTINY-Breast06: T-DXd significantly improves PFS in HER2-low and HER2-ultralow metastatic breast cancer
ASCO 2024
Breast Cancer
monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer
SABCS 2024
Breast Cancer